Ruby Trial & Quizartinib Toxicity
Aug 03, 2023•14 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
The Ruby trial leads to an FDA approval for dostarlimab + chemo in advanced/recurrent endometrial cancer, but only dMMR/MSI-H patients.
Quizartinib's label and REMS program provide some clear, but concerning, warnings about its toxicity.
For the best experience, listen in Metacast app for iOS or Android